Bead Enhancement of EV Analysis

Extracellular vesicles (EVs) are recognized cancer biomarkers, however, clinical analysis has been difficult due to a lack of simple and sensitive assays. Here, we describe a bead-enhanced flow cytometry method, BEAD flow, using biotinylated EVs captured on streptavidin particles. With this method, we show analysis of patient-derived EVs using a panel of pancreatic cancer biomarkers. BEAD flow is easily translatable to any biomarker or cancer type and can be run with conventional flow cytometers, making it highly flexible and adaptable to diverse research and clinical needs.

[1]  Hakho Lee,et al.  Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy , 2017, Science Translational Medicine.

[2]  Jennifer C. Jones,et al.  Labeling Extracellular Vesicles for Nanoscale Flow Cytometry , 2017, Scientific Reports.

[3]  S. Hanash,et al.  Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer , 2017, Journal of the National Cancer Institute.

[4]  Mackenzie A. Eagleson,et al.  A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review , 2017, The American Journal of Gastroenterology.

[5]  Yan Li,et al.  Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring , 2017, Nature Biomedical Engineering.

[6]  Jennifer C. Jones,et al.  Flow Cytometric Analysis of Extracellular Vesicles. , 2017, Methods in molecular biology.

[7]  J. Lötvall,et al.  A rapid, automated surface protein profiling of single circulating exosomes in human blood , 2016, Scientific Reports.

[8]  L. Bujanda,et al.  Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have. , 2016, Annals of translational medicine.

[9]  J. García-Foncillas,et al.  Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? , 2016, BioMed research international.

[10]  Christian Pilarsky,et al.  Glypican-1 identifies cancer exosomes and detects early pancreatic cancer , 2015, Nature.

[11]  M. Büchler,et al.  Combined evaluation of a panel of protein and miRNA serum‐exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity , 2015, International journal of cancer.

[12]  Bob S. Carter,et al.  Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma , 2015, Nature Communications.

[13]  K. R. Jakobsen,et al.  Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma , 2015, Journal of extracellular vesicles.

[14]  I. Sargent,et al.  Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing , 2014, Journal of thrombosis and haemostasis : JTH.

[15]  K. Kinzler,et al.  Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. , 2014, Cancer research.

[16]  Hakho Lee,et al.  Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor , 2014, Nature Biotechnology.

[17]  Hakho Lee,et al.  Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy , 2012, Nature Medicine.

[18]  S. Batra,et al.  Early diagnosis of pancreatic cancer: challenges and new developments. , 2012, Biomarkers in medicine.

[19]  A. Guha,et al.  Extracellular vesicles – vehicles that spread cancer genes , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.

[20]  Ciro Tetta,et al.  Exosome/microvesicle-mediated epigenetic reprogramming of cells. , 2011, American journal of cancer research.

[21]  Bin Zhang.  CD73: a novel target for cancer immunotherapy. , 2010, Cancer research.

[22]  Y. Goto,et al.  Smoking and serum CA19‐9 levels according to Lewis and secretor genotypes , 2008, International Journal of Cancer.

[23]  M. Gönen,et al.  Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma , 2008, Annals of Surgical Oncology.

[24]  Shenmin Zhang,et al.  Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer , 2007, Molecular Cancer Therapeutics.

[25]  J. K. Lee,et al.  Clinical usefulness of carbohydrate antigen 19‐9 as a screening test for pancreatic cancer in an asymptomatic population , 2004, Journal of gastroenterology and hepatology.

[26]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[27]  J. Cameron,et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.